Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06108232 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Name: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma — clinical trial record (NCT06108232)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorM.D. Anderson Cancer Center

Started2024-03-15

View on ClinicalTrials.gov ↗

To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

Amendment history 2 changes detected by DataLookout

2026-09-01

Enrollment reopened

2026-09-01

Enrollment increased: 33 → 83 participants

Trial Details

NCT Number	NCT06108232
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Bristol-Myers Squibb
Conditions	Follicular Lymphoma, Tumor
Enrollment	83 participants
Start Date	2024-03-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-31